fbpx Announcing the ID Neurotoxicity in Immunotherapies QuickFire Challenge - News | JLABS

Announcing the ID Neurotoxicity in Immunotherapies QuickFire Challenge

December 1, 2021 -
1 month ago
JLABS in the Media

December 1, 2021  Johnson & Johnson Innovation together with Janssen Global Services is proud to launch the Improving Detection of Neurotoxicity (“ID Neurotoxicity”) in Immunotherapies QuickFire Challenge with the aim to optimize patient care for immunotherapies within the hematologic malignancy space by enabling early detection of neurotoxic events.

Immunotherapies for treatment of hematologic malignancies, such as T-cell based immunotherapies and chimeric antigen receptor T-cell (CAR-T) therapies, offer a new treatment for these cancers. However, some patients experience neurotoxicity as a result of treatment. Clinical symptoms or signs can be progressive and may include aphasia, altered level of consciousness, impairment of cognitive skills, motor weakness, seizures, and cerebral edema.

Early detection of acute toxicities may enable earlier intervention and ultimately result in improved outcomes for patients. For example, research suggests that analyzing patients’ handwriting may aid in identifying neurotoxicity prior to the presentation of other noticeable symptoms.

The innovator(s) with the best potential solution will receive grant funding up to increments of $200,000, $125,000, and $75,000, access to the global Johnson & Johnson Innovation – JLABS (‘JLABS’) network and mentorship from experts at the Johnson & Johnson Family of Companies (‘Johnson & Johnson’).*

Apply at http://jji.jnj/detect by March 18, 2022.

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.

* Subject to the execution of the necessary documentation and (award) agreements.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.


Related content